Exact Sciences Corp - EXAS STOCK NEWS

Exact Sciences Corp. (EXAS) announced the publication of the RxPONDER trial results in The New England Journal of Medicine. This independent study shows that postmenopausal women with 1 to 3 positive lymph nodes and Oncotype DX Breast Recurrence Score results of 0 to 25 can safely avoid chemotherapy, which spares them from its side effects. The updated NCCN Guidelines now recognize the Oncotype DX test as the only tool for predicting chemotherapy benefit in early-stage breast cancer, potentially impacting treatment for tens of thousands of patients globally.

Exact Sciences Corp. (NASDAQ: EXAS) announced significant findings from a study published in Urologic Oncology, highlighting that adverse pathology in low-risk prostate cancer patients is a strong predictor of worse outcomes. The study involving 428 patients revealed those with adverse pathology were 10 times more likely to develop metastatic disease and eight times more likely to die from prostate cancer. The Oncotype DX Genomic Prostate Score test, designed to assess risk beyond clinical factors, has shown clinical utility in guiding treatment decisions. New tailored patient reports will be launched in December 2021.

Exact Sciences Corp. (NASDAQ: EXAS) has partnered with Jefferson Health to advance research on a novel blood-based, multi-cancer earlier detection (MCED) test. This collaboration targets diverse populations through primary and specialty care providers, focusing on the test's safety and efficacy. Jefferson's network serves over 125,000 adults eligible for cancer screening, and both parties aim to enhance implementation strategies for MCED testing. Key stakeholders will collaborate in a health system-based learning community to develop clinical pathways and potentially publish study results.

Scipher Medicine has appointed Sam Asgarian, M.D., MBA, as its new chief medical officer. Dr. Asgarian brings significant experience from Thrive Earlier Detection Corp., a subsidiary of Exact Sciences (EXAS), and from leadership roles at CVS Health (CVS). His expertise aims to enhance Scipher Medicine's mission to match patients with effective therapies, improving outcomes while reducing costs. The company's flagship test, PrismRA, targets rheumatoid arthritis, addressing the substantial issue of ineffective medication prescriptions that costs over $552 billion annually.

Exact Sciences Corp. (Nasdaq: EXAS) reported third-quarter 2021 revenue of $456.4 million, up 12% from $408.4 million in Q3 2020. Screening revenue rose 31% to $280.4 million, while Precision Oncology revenue surged 59% to $145.4 million. However, COVID-19 testing revenue fell 70% to $30.6 million. The company reported a net loss of $166.9 million, improved from $202.5 million a year ago. For 2021, revenue guidance is set between $1,722 million and $1,737 million.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in three upcoming healthcare conferences. These include a fireside chat at the Jefferies London Healthcare Conference on November 16, 2021, at 10:40 a.m. ET; the Stifel Virtual Healthcare Conference on the same day at 3:20 p.m. ET; and the Evercore ISI HealthCONx Virtual Conference on November 30, 2021, at 11:20 a.m. ET. Investors can access webcasts of these events on the company's investor relations website.

Exact Sciences Corp. (NASDAQ: EXAS) announced data showing that Cologuard (mt-sDNA) significantly reduces colorectal cancer (CRC) incidence and mortality compared to annual fecal immunochemical tests (FIT) in a simulated Medicaid population. The patient navigation system included with Cologuard proved to be cost-effective. Dr. Paul Limburg emphasized the importance of enhancing screening rates, particularly in vulnerable groups. These findings will be presented at the ACG conference, reinforcing Cologuard's position in the market as a valuable tool for early CRC detection.

Exact Sciences Corp. (Nasdaq: EXAS) will release its third quarter 2021 financial results on November 2, 2021, after U.S. market close. A conference call to discuss these results will follow at 5 p.m. ET. The webcast will be accessible via the company's website. This follows the company's focus on developing cancer screening and diagnostic tests, including Cologuard and Oncotype tests. Exact Sciences continues to invest in its product pipeline to enhance support for cancer diagnosis and treatment.

Exact Sciences Corp. (Nasdaq: EXAS) announced participation in upcoming virtual investor conferences, inviting investors to join via webcast. The events include a Fireside Chat at the Wells Fargo Virtual Healthcare Conference on September 9, 2021, at 10:40 a.m. EDT, and another at the Baird 2021 Global Healthcare Conference on September 15, 2021, at 12:15 p.m. EDT. Investors can access the webcasts on Exact Sciences' website. Exact Sciences specializes in cancer screening and diagnostics, focusing on innovative solutions to improve patient care.